Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

UT Health San Antonio MD Anderson Cancer Center

Fibrosis as an experimental marker of efficacy outcomes in myelofibrosis 2:14
Fibrosis as an experimental marker of efficacy outcomes in myelofibrosis
Ruben Mesa • 9 Dec 2022
Overview & updates on the MOMENTUM trial comparing momelotinib and danazol in myelofibrosis 1:20
Overview & updates on the MOMENTUM trial comparing momelotinib and danazol in myelofibrosis
Ruben Mesa • 9 Dec 2022
The association between transfusion independence and improved survival in myelofibrosis 1:30
The association between transfusion independence and improved survival in myelofibrosis
Ruben Mesa • 9 Dec 2022
How the MPN field has evolved over the years: novel agents, trials, and more 2:06
How the MPN field has evolved over the years: novel agents, trials, and more
Ruben Mesa • 9 Dec 2022
The promising role of pelabresib in the treatment of MF 1:00
The promising role of pelabresib in the treatment of MF
Ruben Mesa • 26 Aug 2022
The growing role of combination approaches in MF 1:56
The growing role of combination approaches in MF
Ruben Mesa • 26 Aug 2022
The role of stem cell transplantation in MPNs 1:23
The role of stem cell transplantation in MPNs
Ruben Mesa • 26 Aug 2022
The importance of targeting other pathways after JAKi treatment failure 1:01
The importance of targeting other pathways after JAKi treatment failure
Ruben Mesa • 26 Aug 2022
Upcoming agents in ET and PV 1:39
Upcoming agents in ET and PV
Ruben Mesa • 26 Aug 2022
Early myelofibrosis: current treatment approaches and novel strategies 2:01
Early myelofibrosis: current treatment approaches and novel strategies
Ruben Mesa • 26 Aug 2022
Updates on the use of momelotinib for the treatment of MF & clinical trials evaluating this agent 1:26
Updates on the use of momelotinib for the treatment of MF & clinical trials evaluating this agent
Ruben Mesa • 26 Aug 2022
Upcoming trials and novel agents in MPNs 1:44
Upcoming trials and novel agents in MPNs
Ruben Mesa • 11 Apr 2022
Unmet needs in MPN treatment 1:20
Unmet needs in MPN treatment
Ruben Mesa • 11 Apr 2022
Current and future treatment approaches for secondary fibrosis 1:01
Current and future treatment approaches for secondary fibrosis
Ruben Mesa • 11 Apr 2022
Advances in the science and treatment of MPNs 1:49
Advances in the science and treatment of MPNs
Ruben Mesa • 11 Apr 2022
SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia 1:59
SURPASS ET: ropeginterferon versus anagrelide as second line therapy in essential thrombocythemia
Ruben Mesa • 12 Dec 2021
The content of VJHemOnc is intended for healthcare professionals